A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy ...

KalVista Pharmaceuticals has become the latest biotech to face delays to the FDA’s decision-making, as the agency apparently ...

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.

George Medicines announced the FDA approval of its triple therapy polypill for initial treatment of adults with ...

Higher-than-usual doses of radiation in the treatment of inoperable lung cancer can be safely combined with immunotherapy without increasing the risk of severe lung inflammation (pneumonitis).

Main outcome measures Penicillin G concentrations in maternal and umbilical cord blood in relation to time and dose from administration to time of delivery. Results In 44 mother–infant dyads, median ...

In TEMPO-1, fixed 5 mg and 15 mg doses of tavapadon improved outcomes in patients with Parkinson’s disease. TEMPO-2 showed that a flexible dose was also associated with significant improvements.

Lower doses of a common antibiotic can curb hair loss caused by a rare skin condition, a new study says. The antibiotic doxycycline is commonly used to treat lymphocytic scarring alopecia ...

Our primary outcome is shock reversal (no further need or a reduced (≤10% of the maximum dose) vasopressor requirement for 3 hours ... or continuous venovenous hemodiafiltration (CVVHDF) mode.

INDIANAPOLIS — Eli Lilly announced Wednesday the launch of higher doses of Zepbound — and that the company is lowering the price of certain doses. People taking Zepbound, or interested in starting, ...